Roche Applied Science Announces CGX Arrays Designed by Signature Genomics for Microarray-based Cytogenetic Analysis
News Nov 09, 2009
Roche Applied Science will announce the European and Asia Pacific launch of the NimbleGen CGX arrays for microarray-based cytogenetic analysis at a workshop series in four European cities and seven cities in Asia Pacific.
The CGX arrays are designed by Signature Genomic Laboratories (Signature Genomics) and provide high-resolution, genome-wide analysis of chromosomal abnormalities.
Roche NimbleGen will provide arrays with the Signature Genomics design in multiplex array formats to accommodate the simultaneous processing and analysis of 3, 6, or 12 samples. The CGX arrays are supported by a comprehensive microarray workflow from Roche that includes NimbleGen reagents and instrumentation. Signature Genomics will offer full support for data analysis using its Genoglyphix® software.
Dr. Lisa G. Shaffer, President and CEO of Signature Genomics and keynote speaker at the workshop events in Europe said, “As one of the pioneers in the field of genomic analysis, we continuously work toward innovation and improvement in the products and services we provide. We feel that the Roche partnership is a synergistic fit between two great organizations. Like us, Roche is focused on technical excellence and delivering valuable and relevant scientific information.”
“We, at Roche, are excited to be partnering with Signature Genomics, the market leader in molecular cytogenetic analysis,” said Dr. Gerd Maass, CEO of Roche NimbleGen. “This collaboration signifies Roche’s incredible progress in the last year towards designing and manufacturing high-quality microarrays with supporting comprehensive workflow solutions that meet the specific needs of researchers in the field of genetic analysis.”
Single Blood Test 'CancerSEEK' Screens for Eight Cancer TypesNews
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.READ MORE